Edition:
United States

OncoGenex Pharmaceuticals Inc (OGXI.OQ)

OGXI.OQ on NASDAQ Stock Exchange Capital Market

0.48USD
2:20pm EDT
Change (% chg)

$-0.00 (-0.44%)
Prev Close
$0.48
Open
$0.48
Day's High
$0.50
Day's Low
$0.48
Volume
14,645
Avg. Vol
93,201
52-wk High
$1.41
52-wk Low
$0.33

OGXI.OQ

Chart for OGXI.OQ

About

OncoGenex Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company's segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and... (more)
No analyst recommendations are available for OGXI.OQ.

Overall

Beta: 1.78
Market Cap(Mil.): $14.50
Shares Outstanding(Mil.): 30.09
Dividend: --
Yield (%): --

Financials

  OGXI.OQ Industry Sector
P/E (TTM): -- 48.09 29.63
EPS (TTM): -0.67 -- --
ROI: -71.18 -2.54 13.01
ROE: -71.37 5.17 14.16

BRIEF-Oncogenex Pharma and Achieve Life Science announce strategic collaboration with National Institutes of Health

* Oncogenex Pharma says Achieve Life Science and co announce strategic collaboration with National Institutes of Health to advance development of cytisine

Mar 01 2017

BRIEF-Oncogenex Pharma believes cash, cash equivalents, short-term investments to be sufficient to fund currently planned operations for next 12 months

* Oncogenex pharma - believes cash, cash equivalents, short-term investments to be sufficient to fund currently planned operations for at least next 12 months

Feb 23 2017

BRIEF-Oncogenex Pharmaceuticals says committed to further reduction in workforce

* Will eliminate 5 positions and estimates that will incur about $750,000 in cash expenditures as a result

Nov 17 2016

BRIEF-Oncogenex Pharmaceuticals reports Q3 loss per share $0.12

* Oncogenex Pharmaceuticals Inc reports financial results for third quarter 2016

Nov 10 2016

BRIEF-Oncogenex says will cut about 55 pct of company's workforce

* Oncogenex - on October 25, 2016, committed to a restructuring of a portion of company's workforce

Oct 28 2016

BRIEF-OncoGenex announces positive survival results from apatorsen Phase 2 trial in metatstatic bladder cancer

* OncoGenex announces positive survival results from apatorsen Phase 2 Borealis-2 trial in metastatic bladder cancer

Oct 25 2016

BRIEF-Oncogenex says phase 3 ENSPIRIT trial of custirsen in non-small cell lung cancer did not meet primary endpoint

* Oncogenex announces results from the phase 3 ENSPIRIT trial of custirsen in non-small cell lung cancer

Oct 13 2016

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $125.90 -0.36
Novartis AG (NOVN.S) CHF74.15 +0.75
Pfizer Inc. (PFE.N) $34.29 -0.18
Roche Holding Ltd. (ROG.S) CHF252.60 +2.40
Roche Holding Ltd. (RO.S) CHF252.50 +2.00
Merck & Co., Inc. (MRK.N) $63.28 -0.22
Bayer AG (BAYGn.DE) €106.95 +1.90
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €83.30 +0.53
Eli Lilly and Co (LLY.N) $84.42 +0.06

Earnings vs. Estimates